Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.70 Average Price Target from Brokerages

Shares of Sight Sciences, Inc. (NASDAQ:SGHT) have earned an average recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $4.70.

Several brokerages recently weighed in on SGHT. Piper Sandler reaffirmed a “neutral” rating and issued a $6.00 target price (up previously from $5.00) on shares of Sight Sciences in a report on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Friday, May 3rd.

Sight Sciences Trading Up 2.0 %

NASDAQ SGHT opened at $6.67 on Monday. The firm’s 50-day moving average is $6.03 and its two-hundred day moving average is $5.21. The company has a debt-to-equity ratio of 0.31, a current ratio of 13.01 and a quick ratio of 12.42. Sight Sciences has a 12 month low of $1.04 and a 12 month high of $9.31. The stock has a market capitalization of $331.90 million, a P/E ratio of -5.96 and a beta of 2.76.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. The business had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. On average, sell-side analysts anticipate that Sight Sciences will post -1.13 earnings per share for the current year.

Insider Activity at Sight Sciences

In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the transaction, the chief financial officer now owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Paul Badawi sold 12,571 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $63,860.68. Following the completion of the sale, the chief executive officer now owns 5,750,729 shares in the company, valued at approximately $29,213,703.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Alison Bauerlein sold 10,123 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the transaction, the chief financial officer now directly owns 426,248 shares in the company, valued at $2,165,339.84. The disclosure for this sale can be found here. Insiders sold a total of 47,195 shares of company stock valued at $244,193 over the last ninety days. Insiders own 28.90% of the company’s stock.

Institutional Investors Weigh In On Sight Sciences

Hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in Sight Sciences by 180.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock valued at $62,000 after acquiring an additional 7,764 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Sight Sciences by 51.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after purchasing an additional 9,106 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in shares of Sight Sciences during the first quarter worth $59,000. Swiss National Bank grew its position in Sight Sciences by 19.5% in the 3rd quarter. Swiss National Bank now owns 69,314 shares of the company’s stock valued at $234,000 after buying an additional 11,300 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in Sight Sciences by 100.0% in the 3rd quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock valued at $202,000 after buying an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.